Why CNO Financial (CNO) Could Be a Top Value Stock Pick

Value investing is always a very popular strategy, and for good reason. After all, who doesn’t want to find stocks that have low PEs, solid outlooks, and decent dividends? Fortunately for investors looking for this combination, we have identified a strong candidate which may be an impressive value; CNO Financial […]

Value investing is always a very popular strategy, and for good reason. After all, who doesn’t want to find stocks that have low PEs, solid outlooks, and decent dividends?

Fortunately for investors looking for this combination, we have identified a strong candidate which may be an impressive value; CNO Financial Group, Inc. CNO.

CNO Financial in Focus

CNO may be an interesting play thanks to its forward PE of 8.4, its P/S ratio of 0.6, and its decent dividend yield of 2.9%. These factors suggest that CNO Financial is a pretty good value pick, as investors have to pay a relatively low level for each dollar of earnings, and that CNO has decent revenue metrics to back up its earnings.

CNO Financial Group, Inc. PE Ratio (TTM)

CNO Financial Group, Inc. pe-ratio-ttm | CNO Financial Group, Inc. Quote

But before you think that CNO Financial is just a pure value play, it is important to note that it has been seeing solid activity on the earnings estimate front as well. For current year earnings, the consensus has gone up by 11.1% in the past 30 days, thanks to three upward revisions in the past one month compared to none lower.

This estimate strength is actually enough to push CNO to a Zacks Rank #2 (Buy), suggesting it is poised to outperform. You can see the complete list of today’s Zacks #1 Rank stocks here.

So really, CNO Financial is looking great from a number of angles thanks to its PE below 20, a P/S ratio below one, and a strong Zacks Rank, meaning that this company could be a great choice for value investors at this time.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Click to get this free report

CNO Financial Group, Inc. (CNO): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Next Post

U.S. financial firms like Citi and BlackRock make inroads into China

Wed Sep 2 , 2020
Aerial view of Lujiazui Financial District at dusk, Pudong, Shanghai, China. Fei Yang | Moment | Getty Images From regulatory approval to business decisions, major American financial giants are moving deeper into the Chinese market, even though political tensions between the two countries are growing. Citi announced Wednesday it received a […]
U.S. financial firms like Citi and BlackRock make inroads into China